The TAM family: Phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer

Nature Reviews Cancer

Volumn 14, Issue 12, 2014, Pages 769-785

  Graham, Douglas K ^a   Deryckere, Deborah ^a   Davies, Kurtis D ^a   Earp, H Shelton ^b  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; TAM PROTEIN; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; MERTK PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLSERINE; PROTEIN TYROSINE KINASE;

ANGIOGENESIS; APOPTOSIS; BONE MARROW DERIVED MACROPHAGE; CANCER PATIENT; CELL MEMBRANE; CHEMOSENSITIVITY; DRUG EFFICACY; GENE EXPRESSION; HUMAN; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR MICROENVIRONMENT; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; METABOLISM; NEOPLASM; NEOVASCULARIZATION, PATHOLOGIC; PHYSIOLOGY;

DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNITY, INNATE; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLSERINES; PLATELET AGGREGATION; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84922481128     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3847     Document Type: Review

References (199)

1. Graham, D. K., Dawson, T. L., Mullaney, D. L., Snodgrass, H. R. & Earp, H. S. Cloning and mRNA expression analysis of a novel human protooncogene, c mer. Cell Growth Differ. 5, 647-657 (1994
2. O'Bryan, J. P. et al. AXL, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol. Cell. Biol. 11, 5016-5031 (1991
3. Lai, C., Gore, M. & Lemke, G. Structure, expression, and activity of Tyro 3, a neural adhesion-related receptor tyrosine kinase. Oncogene 9, 2567-2578 (1994
4. Linger, R. M., Keating, A. K., Earp, H. S. & Graham, D. K. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv. Cancer Res. 100, 35-83 (2008
5. Lemke, G. & Rothlin, C. V. Immunobiology of the TAM receptors. Nature Rev. Immunol. 8, 327-336 (2008
6. Ling, L. & Kung, H. J. Mitogenic signals and transforming potential of NYK, a newly identified neural cell adhesion molecule-related receptor tyrosine kinase. Mol. Cell. Biol. 15, 6582-6592 (1995
7. Lapraz, F. et al. RTK and TGF-β signaling pathways genes in the sea urchin genome. Dev. Biol. 300, 132-152 (2006
8. Lai, C. & Lemke, G. An extended family of protein-Tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron 6, 691-704 (1991
9. Jia, R., Mayer, B. J., Hanafusa, T. & Hanafusa, H. A novel oncogene, v RYK, encoding a truncated receptor tyrosine kinase is transduced into the RPL30 virus without loss of viral sequences. J. Virol. 66, 5975-5987 (1992
10. Keating, A. K. et al. Lymphoblastic leukemia/lymphoma in mice overexpressing the MER (MERTK) receptor tyrosine kinase. Oncogene 25, 6092-6100 (2006
11. Guttridge, K. L. et al. MER receptor tyrosine kinase signaling: prevention of apoptosis and alteration of cytoskeletal architecture without stimulation or proliferation. J. Biol. Chem. 277, 24057-24066 (2002
12. Goruppi, S., Ruaro, E., Varnum, B. & Schneider, C. GAS6 mediated survival in NIH3T3 cells activates stress signalling cascade and is independent of RAS. Oncogene 18, 4224-4236 (1999
13. Melaragno, M. G. et al. GAS6 inhibits apoptosis in vascular smooth muscle: role of AXL kinase and AKT. J. Mol. Cell Cardiol. 37, 881-887 (2004
14. Bellosta, P., Zhang, Q., Goff, S. P. & Basilico, C. Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation. Oncogene 15, 2387-2397 (1997
15. Varnum, B. C. et al. AXL receptor tyrosine kinase stimulated by the vitamin K dependent protein encoded by growth-Arrest-specific gene 6. Nature 373, 623-626 (1995
16. Stitt, T. N. et al. The anticoagulation factor protein S and its relative, GAS6, are ligands for the TYRO3/AXL family of receptor tyrosine kinases. Cell 80, 661-670 (1995
17. Nagata, K. et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for AXL, SKY, and MER receptor tyrosine kinases. J. Biol. Chem. 271, 30022-30027 (1996
18. Sasaki, T. et al. Structural basis for GAS6-AXL signalling. EMBO J. 25, 80-87 (2006
19. Tsou, W. I. et al. Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation. J. Biol. Chem. 289, 25750-25763 (2014
20. Lew, E. D. et al. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities. eLife 3, e03385 (2014
21. Zagorska, A., Traves, P. G., Lew, E. D., Dransfield, I. & Lemke, G. Diversification of TAM receptor tyrosine kinase function. Nature Immunol. 15, 920-928 (2014
22. Caberoy, N. B., Zhou, Y. & Li, W. Tubby and tubby-like protein 1 are new MERTK ligands for phagocytosis. EMBO J. 29, 3898-3910 (2010
23. Caberoy, N. B., Alvarado, G. & Li, W. Tubby regulates microglial phagocytosis through MERTK. J. Neuroimmunol. 252, 40-48 (2012
24. Caberoy, N. B., Alvarado, G., Bigcas, J. L. & Li, W. Galectin 3 is a new MERTK-specific eat me signal. J. Cell. Physiol. 227, 401-407 (2012
25. Scott, R. S. et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 411, 207-211 (2001
26. Chen, C. et al. Mer receptor tyrosine kinase signaling participates in platelet function. Arterioscler Thromb. Vasc. Biol. 24, 1118-1123 (2004
27. Angelillo-Scherrer, A. et al. Role of GAS6 in erythropoiesis and anemia in mice. J. Clin. Invest. 118, 583-596 (2008
28. Eken, C. et al. Ectosomes released by polymorphonuclear neutrophils induce a MERTK-dependent anti-inflammatory pathway in macrophages. J. Biol. Chem. 285, 39914-39921 (2010
29. Mercer, J. & Helenius, A. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 320, 531-535 (2008
30. Bhattacharyya, S. et al. Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host Microbe 14, 136-147 (2013
31. Cook, R. S. et al. MERTK inhibition in tumor leukocytes decreases tumor growth and metastasis. J. Clin. Invest. 123, 3231-3242 (2013
32. Paolino, M. et al. The E3 ligase Cbl b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 507, 508-512 (2014
33. Rothlin, C. V., Ghosh, S., Zuniga, E. I., Oldstone, M. B. & Lemke, G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131, 1124-1136 (2007
34. Seitz, H. M., Camenisch, T. D., Lemke, G., Earp, H. S. & Matsushima, G. K. Macrophages and dendritic cells use different AXL/MERTK/TYRO3 receptors in clearance of apoptotic cells. J. Immunol. 178, 5635-5642 (2007
35. Filardy, A. A. et al. Proinflammatory clearance of apoptotic neutrophils induces an IL 12lowIL 10high regulatory phenotype in macrophages. J. Immunol. 185, 2044-2050 (2010
36. D'Cruz, P. M. et al. Mutation of the receptor tyrosine kinase gene MERTK in the retinal dystrophic RCS rat. Hum. Mol. Genet. 9, 645-651 (2000
37. Gal, A. et al. Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nature Genet. 26, 270-271 (2000
38. Duncan, J. L. et al. An RCS-like retinal dystrophy phenotype in Mer-knockout mice. Invest. Ophthalmol. Vis. Sci. 44, 826-838 (2003
39. Conlon, T. J. et al. Preclinical potency and safety studies of an AAV2 mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa. Hum. Gene Ther. Clin. Dev. 24, 23-28 (2013
40. Sandahl, M., Hunter, D. M., Strunk, K. E., Earp, H. S. & Cook, R. S. Epithelial cell-directed efferocytosis in the post-partum mammary gland is necessary for tissue homeostasis and future lactation. BMC Dev. Biol. 10, 122 (2010
41. Shao, W. H. et al. A protective role of MER receptor tyrosine kinase in nephrotoxic serum-induced nephritis. Clin. Immunol. 136, 236-244 (2010
42. Sun, B. et al. Sertoli cell-initiated testicular innate immune response through Toll-like receptor 3 activation is negatively regulated by TYRO3, AXL, and MER receptors. Endocrinology 151, 2886-2897 (2010
43. Ji, R. et al. TAM receptors affect adult brain neurogenesis by negative regulation of microglial cell activation. J. Immunol. 191, 6165-6177 (2013
44. Chung, W. S. et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature 504, 394-400 (2013
45. Zizzo, G., Hilliard, B. A., Monestier, M. & Cohen, P. L. Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MERTK induction. J. Immunol. 189, 3508-3520 (2012
46. Shao, W. H., Zhen, Y., Eisenberg, R. A. & Cohen, P. L. The MER receptor tyrosine kinase is expressed on discrete macrophage subpopulations and mainly uses GAS6 as its ligand for uptake of apoptotic cells. Clin. Immunol. 133, 138-144 (2009
47. Lee-Sherick, A. B. et al. Aberrant MER receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene 32, 5359-5368 (2013
48. Mahajan, N. P. & Earp, H. S. An SH2 domain-dependent, phosphotyrosine-independent interaction between VAV1 and the MER receptor tyrosine kinase: a mechanism for localizing guanine nucleotide-exchange factor action. J. Biol. Chem. 278, 42596-42603 (2003
49. Lee, Y. J. et al. Preventing cleavage of MER promotes efferocytosis and suppresses acute lung injury in bleomycin treated mice. Toxicol. Appl. Pharmacol. 263, 61-72 (2012
50. Wan, E. et al. Enhanced efferocytosis of apoptotic cardiomyocytes through myeloid-epithelial-reproductive tyrosine kinase links acute inflammation resolution to cardiac repair after infarction. Circ. Res. 113, 1004-1012 (2013
51. Camenisch, T. D., Koller, B. H., Earp, H. S. & Matsushima, G. K. A novel receptor tyrosine kinase, MER, inhibits TNFa production and lipopolysaccharide-induced endotoxic shock. J. Immunol. 162, 3498-3503 (1999
52. Tibrewal, N. et al. Autophosphorylation docking site Tyr 867 in MER receptor tyrosine kinase allows for dissociation of multiple signaling pathways for phagocytosis of apoptotic cells and down-modulation of lipopolysaccharide-inducible NF-κB transcriptional activation. J. Biol. Chem. 283, 3618-3627 (2008
53. Sen, P. et al. Apoptotic cells induce MER tyrosine kinase-dependent blockade of NF-κB activation in dendritic cells. Blood 109, 653-660 (2007
54. Wallet, M. A. et al. MERTK is required for apoptotic cell-induced T cell tolerance. J. Exp. Med. 205, 219-232 (2008
55. Alciato, F., Sainaghi, P. P., Sola, D., Castello, L. & Avanzi, G. C. TNFa, IL 6, and IL 1 expression is inhibited by GAS6 in monocytes/macrophages. J. Leukoc. Biol. 87, 869-875 (2010
56. Park, H. J., Baen, J. Y., Lee, Y. J., Choi, Y. H. & Kang, J. L. The TAM-family receptor MER mediates production of HGF through the RHOA-dependent pathway in response to apoptotic cells. Mol. Biol. Cell 23, 3254-3265 (2012
57. Carrera Silva, E. A. et al. T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response. Immunity 39, 160-170 (2013
58. Cohen, P. L. et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c MER membrane tyrosine kinase. J. Exp. Med. 196, 135-140 (2002
59. Lu, Q. & Lemke, G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the TYRO3 family. Science 293, 306-311 (2001
60. Rothlin, C. V., Leighton, J. A. & Ghosh, S. TYRO3, AXL, and MERTK receptor signaling in inflammatory bowel disease and colitis-Associated cancer. Inflamm. Bowel Dis. 20, 1472-1480 (2014
61. Zahuczky, G., Kristof, E., Majai, G. & Fesus, L. Differentiation and glucocorticoid regulated apopto-phagocytic gene expression patterns in human macrophages. Role of MERTK in enhanced phagocytosis. PLoS ONE 6, e21349 (2011
62. A. Gonzalez, N. et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31, 245-258 (2009
63. Kaller, M. et al. Genome-wide characterization of miR 34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol. Cell Proteomics 10, M111 010462 (2011
64. Mudduluru, G. et al. Regulation of AXL receptor tyrosine kinase expression by miR 34a and miR 199a/b in solid cancer. Oncogene 30, 2888-2899 (2011
65. Mackiewicz, M. et al. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR 34a microRNA. Breast Cancer Res. Treat. 130, 663-679 (2011
66. Giles, K. M. et al. AXL mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol. Cancer Ther. 12, 2541-2558 (2013
67. Png, K. J., Halberg, N., Yoshida, M. & Tavazoie, S. F. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 481, 190-194 (2012
68. Wang, C. P. et al. Identification of a gene encoding a typical ?-carboxyglutamic acid domain in the tunicate Halocynthia roretzi. J. Thromb. Haemost. 1, 118-123 (2003
69. Kulman, J. D. et al. Vitamin K dependent proteins in Ciona intestinalis, a basal chordate lacking a blood coagulation cascade. Proc. Natl Acad. Sci. USA 103, 15794-15799 (2006
70. Chen, J., Carey, K. & Godowski, P. J. Identification of GAS6 as a ligand for MER, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. Oncogene 14, 2033-2039 (1997
71. Burstyn-Cohen, T. et al. Genetic dissection of TAM receptor-ligand interaction in retinal pigment epithelial cell phagocytosis. Neuron 76, 1123-1132 (2012
72. Angelillo-Scherrer, A. et al. Deficiency or inhibition of GAS6 causes platelet dysfunction and protects mice against thrombosis. Nature Med. 7, 215-221 (2001
73. Angelillo-Scherrer, A. et al. Role of GAS6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J. Clin. Invest. 115, 237-246 (2005
74. Linger, R. M. et al. MER receptor tyrosine kinase is a therapeutic target in pre B cell acute lymphoblastic leukemia. Blood 122, 1599-1609 (2013
75. Brandao, L. N. et al. Inhibition of MERTK increases chemosensitivity and decreases oncogenic potential in T cell acute lymphoblastic leukemia. Blood Cancer J. 3, e101 (2013
76. Waizenegger, J. S. et al. Role of growth arrest-specific gene 6-MER axis in multiple myeloma. Leukemia http://dx.doi.org/10.1038/leu.2014.236 (2014
77. Neubauer, A. et al. Expression of AXL, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 84, 1931-1941 (1994
78. Rochlitz, C. et al. AXL expression is associated with adverse prognosis and with expression of BCL 2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 13, 1352-1358 (1999
79. Park, I. K. et al. Inhibition of the receptor tyrosine kinase AXL impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for AXL as a potential therapeutic target. Blood 121, 2064-2073 (2013
80. Ben-Batalla, I. et al. AXL, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood 122, 2443-2452 (2013
81. Dirks, W. et al. Expression of the growth arrest-specific gene 6 (GAS6) in leukemia and lymphoma cell lines. Leuk. Res. 23, 643-651 (1999
82. Ghosh, A. K. et al. The novel receptor tyrosine kinase AXL is constitutively active in B cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood 117, 1928-1937 (2011
83. Crosier, P. S., Hall, L. R., Vitas, M. R., Lewis, P. M. & Crosier, K. E. Identification of a novel receptor tyrosine kinase expressed in acute myeloid leukemic blasts. Leuk. Lymphoma 18, 443-449 (1995
84. De Vos, J. et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 98, 771-780 (2001
85. Nelson, E. R. et al. 27 Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342, 1094-1098 (2013
86. Li, Y. et al. The c MER gene is induced by Epstein-Barr virus immediate-early protein BRLF1. J. Virol. 78, 11778-11785 (2004
87. Rankin, E. B. et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc. Natl Acad. Sci. USA 111, 13373-13378 (2014
88. Hong, C. C. et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett. 268, 314-324 (2008
89. Mudduluru, G. & Allgayer, H. The human receptor tyrosine kinase Axl gene - promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci. Rep. 28, 161-176 (2008
90. Liu, R. et al. Induction, regulation, and biologic function of AXL receptor tyrosine kinase in Kaposi sarcoma. Blood 116, 297-305 (2010
91. Kubo, T. et al. Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer. Carcinogenesis 30, 1857-1864 (2009
92. Margareto, J. et al. DNA copy number variation and gene expression analyses reveal the implication of specific oncogenes and genes in GBM. Cancer Invest. 27, 541-548 (2009
93. Tworkoski, K. A. et al. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Pigment Cell. Melanoma Res. 26, 527-541 (2013
94. Seo, J. S. et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 22, 2109-2119 (2012
95. Nguyen, K. Q. et al. Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain of function capacity. J. Biol. Chem. 289, 25737-25749 (2014
96. Linger, R. M. et al. MER or AXL receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene 32, 3420-3431 (2013
97. Shiozawa, Y. et al. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12, 116-127 (2010
98. Shiozawa, Y., Pedersen, E. A. & Taichman, R. S. GAS6/ MER axis regulates the homing and survival of the E2A/PBX1 positive B cell precursor acute lymphoblastic leukemia in the bone marrow niche. Exp. Hematol. 38, 132-140 (2010
99. Georgescu, M. M., Kirsch, K. H., Shishido, T., Zong, C. & Hanafusa, H. Biological effects of c MER receptor tyrosine kinase in hematopoietic cells depend on the GRB2 binding site. Mol. Cell. Biol. 19, 1171-1181 (1999
100. Darby, C., Giannola, D. M., Couzens, M. S. & Emerson, S. G. ETK2 receptor tyrosine kinase promotes survival of factor-dependent FDC P1 progenitor cells. Exp. Hematol. 28, 716-725 (2000
101. Fan, L. et al. Expression of MER on Jurkat cells and its anti-Apoptosis effect. Ai Zheng 26, 698-702 (2007) (in Chinese
102. Rogers, A. E. et al. MER receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology. Oncogene 31, 4171-4181 (2012
103. Schlegel, J. et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J. Clin. Invest. 123, 2257-2267 (2013
104. Brown, J. E., Krodel, M., Pazos, M., Lai, C. & Prieto, A. L. Cross-phosphorylation, signaling and proliferative functions of the TYRO3 and AXL receptors in Rat2 cells. PLoS ONE 7, e36800 (2012
105. Migdall-Wilson, J. et al. Prolonged exposure to a MER ligand in leukemia: GAS6 favors expression of a partial MER glycoform and reveals a novel role for MER in the nucleus. PLoS ONE 7, e31635 (2012
106. Lee, W. P., Wen, Y., Varnum, B. & Hung, M. C. AKT is required for AXL-GAS6 signaling to protect cells from E1A mediated apoptosis. Oncogene 21, 329-336 (2002
107. Graham, D. K. et al. Ectopic expression of the proto-oncogene MER in pediatric T cell acute lymphoblastic leukemia. Clin. Cancer Res. 12, 2662-2669 (2006
108. Li, Y. et al. AXL as a potential therapeutic target in cancer: role of AXL in tumor growth, metastasis and angiogenesis. Oncogene 28, 3442-3455 (2009
109. Hector, A. et al. The AXL receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol. Ther. 10, 1009-1018 (2010
110. Holland, S. J. et al. R428, a selective small molecule inhibitor of AXL kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 70, 1544-1554 (2010
111. Ye, X. et al. An anti-AXL monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29, 5254-5264 (2010
112. Sensi, M. et al. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional AXL receptor kinase. J. Invest. Dermatol. 131, 2448-2457 (2011
113. Song, X. et al. Overexpression of receptor tyrosine kinase AXL promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 117, 734-743 (2011
114. Christoph, S. et al. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol. Cancer Ther. 12, 2367-2377 (2013
115. Leconet, W. et al. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene http://dx.doi.org/10.1038/ onc.2013.487 (2013
116. Keating, A. K. et al. Inhibition of MER and AXL receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol. Cancer Ther. 9, 1298-1307 (2010
117. Dunne, P. D. et al. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clin. Cancer Res. 20, 164-175 (2014
118. Lay, J. D. et al. Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res. 67, 3878-3887 (2007
119. Tai, K. Y., Shieh, Y. S., Lee, C. S., Shiah, S. G. & Wu, C. W. AXL promotes cell invasion by inducing MMP 9 activity through activation of NF-κB and Brg 1. Oncogene 27, 4044-4055 (2008
120. Paccez, J. D. et al. The receptor tyrosine kinase AXL is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene 32, 689-698 (2013
121. Asiedu, M. K. et al. AXL induces epithelial-To mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene 33, 1316-1324 (2014
122. Lee, C. H. et al. Tumor-Associated macrophages promote oral cancer progression through activation of the AXL signaling pathway. Ann. Surg. Oncol. 21, 1031-1037 (2014
123. Papadakis, E. S. et al. AXL promotes cutaneous squamous cell carcinoma survival through negative regulation of pro-Apoptotic BCL 2 family members. J. Invest. Dermatol. 131, 509-517 (2011
124. Nur, E. K. A. et al. Requirement of activated CDC42 associated kinase for survival of v RAS-Transformed mammalian cells. Mol. Cancer Res. 3, 297-305 (2005
125. Melaragno, M. G., Fridell, Y. W. & Berk, B. C. The GAS6/AXL system: a novel regulator of vascular cell function. Trends Cardiovasc. Med. 9, 250-253 (1999
126. Ruan, G. X. & Kazlauskas, A. AXL is essential for VEGF A dependent activation of PI3K/AKT. EMBO J. 31, 1692-1703 (2012
127. Fraineau, S. et al. The vitamin K dependent anticoagulant factor, protein S, inhibits multiple VEGF A induced angiogenesis events in a MER- and SHP2 dependent manner. Blood 120, 5073-5083 (2012
128. Suleiman, L., Negrier, C. & Boukerche, H. Protein S: A multifunctional anticoagulant vitamin K dependent protein at the crossroads of coagulation, inflammation, angiogenesis, and cancer. Crit. Rev. Oncol. Hematol. 88, 637-654 (2013
129. Burstyn-Cohen, T., Heeb, M. J. & Lemke, G. Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. J. Clin. Invest. 119, 2942-2953 (2009
130. Pierce, A. et al. AXL and TYRO3 modulate female reproduction by influencing gonadotropin-releasing hormone neuron survival and migration. Mol. Endocrinol. 22, 2481-2495 (2008
131. Salian-Mehta, S., Xu, M. & Wierman, M. E. AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival. Mol. Cell. Endocrinol. 374, 92-100 (2013
132. Lee, H. J., Jeng, Y. M., Chen, Y. L., Chung, L. & Yuan, R. H. GAS6/AXL pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma. Carcinogenesis 35, 769-775 (2014
133. Allen, M. P. et al. Novel mechanism for gonadotropin-releasing hormone neuronal migration involving GAS6/ARK signaling to p38 mitogen-Activated protein kinase. Mol. Cell. Biol. 22, 599-613 (2002
134. Allen, M. P. et al. Adhesion-related kinase repression of gonadotropin-releasing hormone gene expression requires RAC activation of the extracellular signal-regulated kinase pathway. J. Biol. Chem. 277, 38133-38140 (2002
135. Kariolis, M. S. et al. An engineered AXL 'decoy receptor' effectively silences the GAS6-AXL signaling axis. Nature Chem. Biol. 10, 977-983 (2014
136. Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunol. 11, 889-896 (2010
137. Coussens, L. M., Zitvogel, L. & Palucka, A. K. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 339, 286-291 (2013
138. Rothlin, C. V. & Lemke, G. TAM receptor signaling and autoimmune disease. Curr. Opin. Immunol. 22, 740-746 (2010
139. Khan, T. N., Wong, E. B., Soni, C. & Rahman, Z. S. Prolonged apoptotic cell accumulation in germinal centers of MER-deficient mice causes elevated B cell and CD4+ TH cell responses leading to autoantibody production. J. Immunol. 190, 1433-1446 (2013
140. Franklin, R. A. et al. The cellular and molecular origin of tumor-Associated macrophages. Science 344, 921-925 (2014
141. Ehrchen, J. et al. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 109, 1265-1274 (2007
142. DeNardo, D. G. et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54-67 (2011
143. Pyonteck, S. M. et al. CSF 1R inhibition alters macrophage polarization and blocks glioma progression. Nature Med. 19, 1264-1272 (2013
144. Loges, S. et al. Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen GAS6. Blood 115, 2264-2273 (2010
145. Jacobsen, K. M. et al. Targeted inhibition of MER tyrosine kinase in the tumor microenvironment decreases tumor growth in a mouse model of breast cancer in Proc. 104th Annual Meeting of the American Association for Cancer Research (2013
146. Stanford, J. C. et al. Efferocytosis produces a pro-metastatic landscape during post-partum mammary gland involution. J. Clin. Invest. http://dx.doi. org/10.1172/JCI76375 (2014
147. Zhao, Y. et al. Differential expression of AXL and correlation with invasion and multidrug resistance in cancer cells. Cancer Invest. 30, 287-294 (2012
148. Macleod, K. et al. Altered ERBB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res. 65, 6789-6800 (2005
149. Zhu, S. et al. A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc. Natl Acad. Sci. USA 106, 17025-17030 (2009
150. Wang, Y. et al. MER receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. Oncogene 32, 872-882 (2013
151. Mahadevan, D. et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 26, 3909-3919 (2007
152. Dufies, M. et al. Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Oncotarget 2, 874-885 (2011
153. Gioia, R. et al. Quantitative phosphoproteomics revealed interplay between SYK and LYN in the resistance to nilotinib in chronic myeloid leukemia cells. Blood 118, 2211-2221 (2011
154. Liu, L. et al. Novel mechanism of lapatinib resistance in HER2 positive breast tumor cells: activation of AXL. Cancer Res. 69, 6871-6878 (2009
155. Meyer, A. S., Miller, M. A., Gertler, F. B. & Lauffenburger, D. A. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-Targeted inhibitors in triple-negative breast cancer cells. Sci. Signal. 6, ra66 (2013
156. Ware, K. E. et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis 2, e39 (2013
157. Kim, H. R. et al. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. Mol. Oncol. 7, 1093-1102 (2013
158. Huang, F. et al. Differential mechanisms of acquired resistance to insulin-like growth factor 1 receptor antibody therapy or to a small-molecule inhibitor, BMS 754807, in a human rhabdomyosarcoma model. Cancer Res. 70, 7221-7231 (2010
159. Brand, T. M. et al. AXL mediates resistance to cetuximab therapy. Cancer Res. 74, 5152-5164 (2014
160. Zhang, Z. et al. Activation of the AXL kinase causes resistance to EGFR-Targeted therapy in lung cancer. Nature Genet. 44, 852-860 (2012
161. Khoury, H. J. et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 119, 3403-3412 (2012
162. Zhang, Y. X. et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res. 68, 1905-1915 (2008
163. Knubel, K. H. et al. MERTK inhibition is a novel therapeutic approach for glioblastoma multiforme. Oncotarget 5, 1338-1351 (2014
164. Rettew, A. N. et al. Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines. Oncogenesis 1, e34 (2012
165. Liu, J. et al. Discovery of novel small molecule MER kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia. ACS Med. Chem. Lett. 3, 129-134 (2012
166. Liu, J. et al. UNC1062, a new and potent MER inhibitor. Eur. J. Med. Chem. 65, 83-93 (2013
167. Zhang, W. et al. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J. Med. Chem. 57, 7031-7041 (2014
168. DeRyckere, D. et al. Development of a novel small molecule MER tyrosine kinase inhibitor with therapeutic activity in cell culture and mouse models of acute lymphoblastic leukemia. in Proc. 104th Annual Meeting of the American Association for Cancer Research (2013
169. Earp, H. S. et al. A small molecule MER tyrosine kinase inhibitor (UNC MERTKi) effectively inhibits growth of murine melanoma. in Proc. 104th Annual Meeting of the American Association for Cancer Research (2013
170. Powell, N. A. et al. Novel and selective spiroindoline-based inhibitors of SKY kinase. Bioorg. Med. Chem. Lett. 22, 190-193 (2012
171. Powell, N. A. et al. Optimization of highly selective 2, 4 diaminopyrimidine 5 carboxamide inhibitors of SKY kinase. Bioorg. Med. Chem. Lett. 23, 1051-1055 (2013
172. Powell, N. A. et al. Highly selective 2, 4 diaminopyrimidine 5 carboxamide inhibitors of SKY kinase. Bioorg. Med. Chem. Lett. 23, 1046-1050 (2013
173. Cummings, C. T. et al. Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget 26 June 2014
174. Demarest, S. J. et al. Evaluation of TYRO3 expression, GAS6 mediated AKT phosphorylation, and the impact of anti TYRO3 antibodies in melanoma cell lines. Biochemistry 52, 3102-3118 (2013
175. Cerchia, L. et al. Targeting AXL with an high-Affinity inhibitory aptamer. Mol. Ther. 20, 2291-2303 (2012
176. Avilla, E. et al. Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. Cancer Res. 71, 1792-1804 (2011
177. Sather, S. et al. A soluble form of the MER receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 109, 1026-1033 (2007
178. Morizono, K. et al. The soluble serum protein GAS6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase AXL to mediate viral entry. Cell Host Microbe 9, 286-298 (2011
179. Shimojima, M. et al. TYRO3 family-mediated cell entry of Ebola and Marburg viruses. J. Virol. 80, 10109-10116 (2006
180. Morizono, K. & Chen, I. S. The role of phosphatidylserine receptors in enveloped virus infection. J. Virol. 88, 4275-4290 (2014
181. Meertens, L. et al. The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe 12, 544-557 (2012
182. Rahman, Z. S., Shao, W. H., Khan, T. N., Zhen, Y. & Cohen, P. L. Impaired apoptotic cell clearance in the germinal center by MER-deficient tingible body macrophages leads to enhanced antibody-forming cell and germinal center responses. J. Immunol. 185, 5859-5868 (2010
183. Williams, J. C., Wagner, N. J., Earp, H. S., Vilen, B. J. & Matsushima, G. K. Increased hematopoietic cells in the Mertk-/- mouse peritoneal cavity: a result of augmented migration. J. Immunol. 184, 6637-6648 (2010
184. Weinger, J. G. et al. Loss of the receptor tyrosine kinase AXL leads to enhanced inflammation in the CNS and delayed removal of myelin debris during experimental autoimmune encephalomyelitis. J. Neuroinflamm. 8, 49 (2011
185. Subramanian, M. et al. An AXL/LRP1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo. J. Clin. Invest. 124, 1296-1308 (2014
186. Bosurgi, L. et al. Paradoxical role of the proto-oncogene AXL and MER receptor tyrosine kinases in colon cancer. Proc. Natl Acad. Sci. USA 110, 13091-13096 (2013
187. Tang, H. et al. TAM receptors and the regulation of erythropoiesis in mice. Haematologica 94, 326-334 (2009
188. Lu, Q. et al. TYRO3 family receptors are essential regulators of mammalian spermatogenesis. Nature 398, 723-728 (1999
189. Li, Q., Lu, Q., Lu, H., Tian, S. & Lu, Q. Systemic autoimmunity in TAM triple knockout mice causes inflammatory brain damage and cell death. PLoS ONE 8, e64812 (2013
190. Qi, N. et al. Development of a spontaneous liver disease resembling autoimmune hepatitis in mice lacking TYRO3, AXL and MER receptor tyrosine kinases. PLoS ONE 8, e66604 (2013
191. Caraux, A. et al. Natural killer cell differentiation driven by TYRO3 receptor tyrosine kinases. Nature Immunol. 7, 747-754 (2006
192. Wang, H. et al. The role of TYRO 3 subfamily receptors in the regulation of hemostasis and megakaryocytopoiesis. Haematologica 92, 643-650 (2007
193. Binder, M. D. et al. GAS6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination. J. Neurosci. 28, 5195-5206 (2008
194. Binder, M. D. et al. GAS6 increases myelination by oligodendrocytes and its deficiency delays recovery following cuprizone-induced demyelination. PLoS ONE 6, e17727 (2011
195. Fourcot, A. et al. GAS6 deficiency prevents liver inflammation, steatohepatitis, and fibrosis in mice. Am. J. Physiol-Gaster. L. 300, G1043-G1053 (2011
196. Hagstrom, S. A., Duyao, M., North, M. A. & Li, T. Retinal degeneration in Tulp1-/- mice: vesicular accumulation in the interphotoreceptor matrix. Invest. Ophthalmol. Vis. Sci. 40, 2795-2802 (1999
197. Stubdal, H. et al. Targeted deletion of the tub mouse obesity gene reveals that tubby is a loss of function mutation. Mol. Cell. Biol. 20, 878-882 (2000
198. Sano, H. et al. Critical role of galectin 3 in phagocytosis by macrophages. J. Clin. Invest. 112, 389-397 (2003
199. Abdel-Aziz, H. O. et al. Targeted disruption of the galectin 3 gene results in decreased susceptibility to NNK-induced lung tumorigenesis: an oligonucleotide microarray study. J. Cancer Res. Clin. Oncol. 134, 777-788 (2008